Advertisement
Canada markets closed

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7302
    +0.0005 (+0.07%)
     

  • CRUDE OIL

    82.66
    -0.15 (-0.18%)
     

  • Bitcoin CAD

    87,929.54
    -3,443.10 (-3.77%)
     

  • CMC Crypto 200

    1,387.48
    -36.62 (-2.57%)
     

  • GOLD FUTURES

    2,332.30
    -6.10 (-0.26%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,470.75
    -193.75 (-1.10%)
     

  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    37,776.33
    -683.75 (-1.78%)
     

  • CAD/EUR

    0.6817
    -0.0002 (-0.03%)
     

Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference

Cassava Sciences, Inc.
·1 min read
Cassava Sciences, Inc.
Cassava Sciences, Inc.

AUSTIN, Texas, April 26, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that Remi Barbier, President & Chief Executive Officer, has been invited to present at the 2023 H.C. Wainwright BioConnect Investor Conference in New York. In addition, management will be available for one-on-one meetings with institutional investors who are registered to attend this conference.

When: Tuesday, May 2nd at 3pm Eastern time

Live Webcast: https://journey.ct.events/view/f51ce8f9-51a5-45e8-891b-e3623ecb6305

ADVERTISEMENT

Archived Replay: https://www.CassavaSciences.com/company-presentations

About Cassava Sciences, Inc.
Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease. Our novel science is based on stabilizing—but not removing—a critical protein in the brain. Our product candidates have not been approved by any regulatory authority, and their safety, efficacy or other desirable attributes have not been established. For more information, please visit: https://www.CassavaSciences.com.

For More Information Contact:
Eric Schoen, Chief Financial Officer
(512) 501-2450 or ESchoen@CassavaSciences.com